Inhibition of HIF1A-As2 suppresses tumor cell proliferation and increases tumor sensitivity to cisplatin treatment, indicating the potential therapeutic value of targeting this lncRNA in KRAS-driven NSCLC [53]. Here, KRAS is linked to neoplasm.